Department of Surgery, Providence Hospital and Medical Centers, Southfield, MI, USA.
HPB (Oxford). 2007;9(4):289-94. doi: 10.1080/13651820701329241.
Interferons (IFNs) are known to have antiproliferative and immunoregulatory activities that are modulated through specific cell surface ligands, known as IFN-alpha, -beta, and -gamma receptors. The presence of these receptors and their impact on response to adjuvant therapy in patients with pancreatic cancer has not been determined.
Slides were prepared from 46 patients with pancreatic adenocarcinoma. Immunohistochemistry (IHC) was subsequently used to determine the expression of IFN- alpha/beta receptor-chain 2 (IFN-alpha/betaR) and IFN-gamma receptor-chain 1 (IFN-gammaR). The correlation between IFN receptor expression, tumor characteristics, and the overall patient response to adjuvant therapy were determined analytically.
The IHC performed for pancreatic adenocarcinoma demonstrated a high IFN-alpha/betaR expression in 4% (2/46) of patients, moderate expression in 20% (9/46) of patients, and faint or no expression in 76% (35/46) of patients. IHC confirmed a high expression of IFN-gammaR in 52% (24/46) of patients, moderate expression in 35% (16/46) of patients, and faint or no expression in the remaining 13% (6/46) of patients. Thirty-two (69.7%) patients received adjuvant therapy. Clinicopathological survey did not demonstrate any significant correlation between IFN-alpha/betaR and IFN-gammaR expression with regard to tumor size, vascular invasion, perineural invasion, lymph node metastases, or stage of disease. Use of adjuvant therapy was associated with increased survival in patients with IFN-alpha/betaR-positive tumors compared with patients with IFN-alpha/betaR-negative tumors (24 months versus 14.7 months in log rank test, p=0.012). The expression of IFN-gammaR, however, had no impact on patient survival (20 months vs 17 months; p=0.656, log rank test).
IFN-alpha/betaR is associated with improved survival for patients with resectable pancreatic cancer who received adjuvant therapy.
干扰素（IFN）具有抗增殖和免疫调节作用，其通过特定的细胞表面配体（称为 IFN-α、β和-γ受体）进行调节。这些受体的存在及其对接受辅助治疗的胰腺癌患者的反应的影响尚未确定。
从 46 例胰腺腺癌患者中制备切片。随后进行免疫组织化学（IHC）以确定 IFN-α/β受体链 2（IFN-α/βR）和 IFN-γ受体链 1（IFN-γR）的表达。分析确定 IFN 受体表达与肿瘤特征以及患者对辅助治疗的总体反应之间的相关性。
对胰腺腺癌进行的 IHC 显示，4%（2/46）的患者高表达 IFN-α/βR，20%（9/46）的患者中度表达，76%（35/46）的患者低表达或无表达。IHC 证实 52%（24/46）的患者高表达 IFN-γR，35%（16/46）的患者中度表达，其余 13%（6/46）的患者低表达或无表达。32（69.7%）例患者接受了辅助治疗。临床病理调查显示，IFN-α/βR 和 IFN-γR 的表达与肿瘤大小、血管侵犯、神经周围侵犯、淋巴结转移或疾病分期之间均无显著相关性。与 IFN-α/βR 阴性肿瘤患者相比，接受辅助治疗的 IFN-α/βR 阳性肿瘤患者的生存率更高（24 个月与对数秩检验的 14.7 个月，p=0.012）。然而，IFN-γR 的表达对患者的生存没有影响（20 个月与 17 个月；p=0.656，对数秩检验）。
在接受辅助治疗的可切除胰腺癌患者中，IFN-α/βR 与生存改善相关。
